title: Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity.
abstract: The use of cardenolides like ouabain, digitoxin, or oleandrin has been reported previously many times as a means of potentially combating human refractory prostate cancer by inducing apoptosis through an increase in intracellular calcium concentrations. The aims of the current study were to investigate if part of the antitumor effects mediated by cardenolides concerned disorganization of nucleolar structure and whether this was further associated with a marked decrease in c-Myc expression. Accordingly, the antitumor activity of a novel hemisynthetic cardenolide [1R,3aS,3bR,5aS,6aR,7aS,9R,12aR,13aR,15aR]-3a,11a-dihydroxy-13a-(hydroxymethyl)-9,15a-dimethyl-1-(5-oxo-2,5-dihydrofuran-3-yl)icosahydro-1H,4'H-spiro[cyclopenta [7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxine-11,2'-[1,3]thiazolidin]-4'-one (UNBS1450)] was compared with that of classic cardenolides and reference anticancer agents in prostate cancer cell lines in vitro and in vivo following s.c. and orthotopic prostate cancer cell grafting into mice. The present study indicates that UNBS1450 markedly decreases the in vitro viability/proliferation of human prostate cancer cell lines but not of normal cells. The induced effects are not linked to an increase in intracellular calcium concentrations and subsequent induction of apoptosis. Rather, they appear to relate to the compound's capacity to disorganize nucleolar structure and function (through an impairment of cyclin-dependent kinase and c-Myc expression and related signaling pathways; paralleled by the disorganization of cancer cell-specific perinucleolar bodies as revealed by disruption of Sam68). This nonapoptotic cancer cell death mediated by severe nucleolar targeting and down-regulation of c-Myc expression is a completely new cardenolide-induced mechanism of antitumor action.
authors.affiliation: Unibioscreen SA, Brussels, Belgium.
authors.forename: Tatjana
authors.initials: T
authors.lastname: Mijatovic
authors.forename: Nancy
authors.initials: N
authors.lastname: De Nève
authors.forename: Philippe
authors.initials: P
authors.lastname: Gailly
authors.forename: Véronique
authors.initials: V
authors.lastname: Mathieu
authors.forename: Benjamin
authors.initials: B
authors.lastname: Haibe-Kains
authors.forename: Gianluca
authors.initials: G
authors.lastname: Bontempi
authors.forename: Javier
authors.initials: J
authors.lastname: Lapeira
authors.forename: Christine
authors.initials: C
authors.lastname: Decaestecker
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Facchini
authors.forename: Robert
authors.initials: R
authors.lastname: Kiss
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D002118:Calcium / Q000378:metabolism; D002298:Cardenolides / Q000627:therapeutic use*; D002466:Cell Nucleolus / Q000187:drug effects* / Q000648:ultrastructure; D049109:Cell Proliferation; D015536:Down-Regulation; D006801:Humans; D008297:Male; D051379:Mice; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000648:ultrastructure; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D002298:Cardenolides; D016271:Proto-Oncogene Proteins c-myc; C510008:UNBS 1450; D002118:Calcium